Resverlogix tweet from this afternoon: "#Apabetalone referenced in Nature Reviews Publication: #ALP: a novel treatment target for #CVD in #CKD https://www.ncbi.nlm.nih.gov/pubmed/28502983  @kamkalantar"

https://twitter.com/Resverlogix_RVX/status/864591304210108416

It references this paper: https://www.ncbi.nlm.nih.gov/pubmed/28502983, published in Nature Reviews Nephrology co-authored by Kamyar Kalantar-Zadeh entitled "Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD." I don't have access to the paper, but it does reference 2 Resverlogix published papers, 2 Resverlogix presented abstracts and the BETonMACE trial. The last two sentences of the abstract indicate that they probably gave a shout out to apabetalone:

"Here we review novel mechanisms that link ALP to vascular calcification, inflammation, and endothelial dysfunction in kidney and cardiovascular diseases. We also discuss new drugs that target ALP, which have the potential to improve cardiovascular outcomes without inhibiting skeletal mineralization."

 The ERA-EDTA meeting is less than 3 weeks away, at which there is rumored to be a symposium on BET inhibitors and Renal Disease sponsored by Resverlogix. Nothing official from Resverlogix on this yet, but hopefully it comes to fruition. It would be very timely with the IND/FDA approval of the renal trial happening yesterday.

BDAZ